Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coramitug - Novo Nordisk

Next Previous
Drug Profile

Coramitug - Novo Nordisk

Alternative Names: NN-6019; NNC6019-0001; PRX-004

Latest Information Update: 10 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neotope Biosciences
  • Developer Novo Nordisk
  • Class Cardiovascular therapies; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transthyretin-related hereditary amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Transthyretin-related hereditary amyloidosis
  • No development reported Cardiovascular disorders

Most Recent Events

  • 30 Sep 2025 Novo Nordisk plans a phase III CLEOPATTRA trial for Transthyretin-related hereditary amyloidosis in Australia, Belgium, Brazil, Canada, China, Czech Republic, Denmark, England, France, Germany, Italy, Japan, Multinational, the Netherlands, Scotland, South Korea, Spain, United Kingdom, USA and Wales in September 2025 (IV, Infusion) (NCT07207811)
  • 06 Aug 2025 Novo Nordisk plans phase III trial for Transthyretin-related hereditary amyloidosis (IV, Infusion) in 2025
  • 30 Jun 2025 Novo Nordisk A/S plans a phase I trial for Transthyretin targeted amyloidosis in Netherlands (IV, Infusion) in June 2025 (CTIS2024-519372-22-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top